RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $420 from $408 and keeps a Sector Perform rating on the shares.
ABC News‘ venerable late-night news program “Nightline” is marking its 45th anniversary with an updated ... Read More ...
In a report released today, William Pickering from Bernstein maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback